Company intelligence / Profile preview
Allegrow Biotech
Hong Kong, Hong Kongallegrowbiotech.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Allegrow Biotech has developed artificial cell technology (AimGel) that mimics the immunological synapse to expand and activate immune cells with higher efficiency. Their technology has achieved 60% more cell yields for T cells and almost five times more yield for natural killer cells during cell culture or bioprocessing[4].
- Therapeutic areas
- Immunology
- Modalities
- Artificial cell technologybiomaterial-based approach
- Industry
- Non-Drug Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Allegrow Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allegrow Biotech.